Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
The American Association for the Study of Liver Diseases has updated the treatment guidelines for hepatitis C.
Physicians argue the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait?
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1...
Harvoni (ledipasvir/sofosbuvir) is proving highly successful at treating hepatitis C among people coinfected with HIV and genotype 1 of hep C...
Achieving a cure for hepatitis C through interferon-based treatment reduces the risk of death, liver cancer and needing a liver transplant.
Incivek added to interferon and ribavirin shortens the treatment duration and raises cure rates among gay, HIV-positive men with acute hep C
Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus.
Researchers reveled in promising new data on forthcoming hepatitis C therapies.
The hepatitis C pipeline: huge changes on the horizon
People coinfected with HIV and hepatitis C virus experience high hepatitis cure rates from an Incivek (telaprevir)?based triple combination th...
People with liver cirrhosis may benefit from daily therapy with a blood thinner to prevent portal vein thrombosis (PVT), a potentially serious...
Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclo...
It’s official. Chronic hepatitis C virus (HCV) infection is associated with more deaths than HIV infection, according to sobering new data..
Combining Pharmasset’s once-daily experimental nucleotide analog PSI-7977 with pegylated interferon and ribavirin cured 91 percent of 47 peopl...
A twelve-week course of Pharmasset’s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.